Hereditary persistence of α-fetoprotein -: Case report and review of the literature

被引:40
作者
Schefer, H [1 ]
Mattmann, S [1 ]
Joss, RA [1 ]
机构
[1] Kantonsspital, Dept Med, Div Oncol, CH-6000 Luzern 16, Switzerland
关键词
alpha-fetoprotein; alpha-fetoprotein and clinical use; hereditary persistence of alpha-fetoprotein; tumor marker;
D O I
10.1023/A:1008243311122
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Persistently elevated a-fetoprotein (AFP) levels of 24 to 30 mu g/ml (normal <10 mu g/ml) were found in a 38-year-old healthy man. Subsequently, AFP was found to be elevated in another five out of 13 family members within three generations. The pedigree is consistent with an autosomal dominant inheritance pattern. No discernible disease and no functional abnormality appears to be associated with this clinically benign disorder which has been recorded in the literature on four occasions to date. The reported AFP levels in these other cases ranged from IS to 198 mu g/ml. Physiologically, AFP is mainly produced in the liver and the yolk sac of human fetuses more than four weeks old, with peak values of up to 4 mg/ml at 12 to 16 weeks of gestation. After birth, AFP levels usually fall, within eight to 12 months, to a very low concentration of < 10 mu g/ml and persist at low levels throughout life. However, AFP levels can rise above normal in both children and adults in distinct conditions and diseases which will be discussed. Hereditary persistence of alpha-fetoprotein (HPAFP) should be considered in both children and adults with unexplained and persistent elevation of AFP e.g., those screened for hepatocellular carcinoma or diagnosed for germ cell tumor. It should also be recognized in AFP screening for neural tube defects or Down's syndrome during pregnancy. Hereditary persistence of AFP can be easily confirmed by analyzing AFP levels in family members.
引用
收藏
页码:667 / 672
页数:6
相关论文
共 81 条
[41]   ALPHA-FETOPROTEIN-LECTIN BINDING AS A MARKER OF TUMOR-ACTIVITY OR LIVER-DAMAGE [J].
MARRINK, J ;
SLEIJFER, DT ;
DEVRIES, EGE ;
KOOPS, HS .
EUROPEAN JOURNAL OF CANCER, 1990, 26 (09) :969-972
[42]   OCCURRENCE OF FETOPROTEIN IN PATIENTS WITH NEOPLASMS AND NON-NEOPLASTICS DISEASES [J].
MASOPUST, J ;
KITHIER, K ;
RADL, J ;
KOUTECKY, J ;
KOTAL, L .
INTERNATIONAL JOURNAL OF CANCER, 1968, 3 (03) :364-+
[43]  
MCKUSICK VA, 1994, MENDELIAN INHERITANC, P66
[44]   A G-]A SUBSTITUTION IN AN HNF-I BINDING-SITE IN THE HUMAN ALPHA-FETOPROTEIN GENE IS ASSOCIATED WITH HEREDITARY PERSISTENCE OF ALPHA-FETOPROTEIN (HPAFP) [J].
MCVEY, JH ;
MICHAELIDES, K ;
HANSEN, LP ;
FERGUSONSMITH, M ;
TILGHMAN, S ;
KRUMLAUF, R ;
TUDDENHAM, EGD .
HUMAN MOLECULAR GENETICS, 1993, 2 (04) :379-384
[45]  
Mead GM, 1997, J CLIN ONCOL, V15, P594
[46]   AN ASSOCIATION BETWEEN LOW MATERNAL SERUM ALPHA-FETOPROTEIN AND FETAL CHROMOSOMAL-ABNORMALITIES [J].
MERKATZ, IR ;
NITOWSKY, HM ;
MACRI, JN ;
JOHNSON, WE .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1984, 148 (07) :886-894
[47]   PREDICTIVE VALUES, RELATIVE RISKS, AND OVERALL BENEFITS OF HIGH AND LOW MATERNAL SERUM ALPHA-FETOPROTEIN SCREENING IN SINGLETON PREGNANCIES - NEW EPIDEMIOLOGIC DATA [J].
MILUNSKY, A ;
JICK, SS ;
BRUELL, CL ;
MACLAUGHLIN, DS ;
TSUNG, YK ;
JICK, H ;
ROTHMAN, KJ ;
WILLETT, W .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1989, 161 (02) :291-297
[48]  
MILUNSKY A, 1980, OBSTET GYNECOL, V55, P60
[49]  
Mizejewski G. J., 1985, ALPHA FETOPROTEIN CO, P5
[50]   ALPHA-FETOPROTEIN SIGNAL SEQUENCES - A PROPOSED MECHANISM FOR SUBCELLULAR-LOCALIZATION AND ORGANELLE TARGETING [J].
MIZEJEWSKI, GJ .
JOURNAL OF THEORETICAL BIOLOGY, 1995, 176 (01) :103-113